Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is XWELL, Inc. (XWEL) Stock Down -15.32% Today?

Why Is XWELL, Inc. (XWEL) Stock Down -15.32% Today?

Key Takeaways

  • XWELL, Inc. (XWEL) shares fell 15.32% to $0.4183 in the first half hour of Tuesday trading, down from Monday's close of $0.494.
  • The primary catalyst was a late Monday filing of Form 12b-25, notifying investors that the company's Form 10-Q for the quarter ended September 30, 2026, would be filed late.
  • The delay lands on top of an unresolved Nasdaq minimum bid price deficiency and a pending $13 million sale of XpresSpa and XpresTest to Express Wellness Group.
  • Turnover was heavy for a micro-cap with a float near 5.8 million shares: roughly 47,000 shares traded in the first 26 minutes, more than a typical full session.
  • Broader indices were essentially flat — the S&P 500, Nasdaq-100 proxies and small-cap benchmarks were all within 0.2% of Monday's close — so the selloff was company-specific.
  • News Significance Score: 52/100 — a moderate compliance setback met a slide more than four times the stock's typical daily swing.
  • Traders are watching whether the quarterly report arrives within the promised five-day window and whether the bid price recovers toward $1.
  • More detail on XWELL is available on Tickeron's Price Targets, Earnings and Forecast pages.
  • Investors seeking live strategy ideas can explore Trending AI Robots on Tickeron.

Opening Summary

XWELL, Inc. (XWEL) is a New York-based wellness holding company, formerly known as XpresSpa Group, that operates airport spa and health services brands including XpresSpa, XpresCheck and Naples Wax Center. The company has a market capitalization of roughly $4.4 million and a 52-week range of $0.2551 to $2.20.

Shares traded at $0.4183 early Tuesday, down 15.32% from Monday's close of $0.494. The direction is unambiguously lower. At the session low, the stock touched $0.302, a decline of nearly 39%, before recovering some ground. The immediate cause cited by the market was the company's Monday-evening disclosure that its quarterly report would not be filed on time.

A Late Quarterly Filing Removes a Key Information Event

After Monday's close, XWELL filed a Form 12b-25 with securities regulators stating that its Form 10-Q for the period ended September 30, 2026, could not be completed without unreasonable effort and expense. Management said it needs additional time to compile and analyze supporting documentation, finish preparing its financial statements and complete the review process. The notice identified no auditor change or committee investigation behind the delay, and the company said it intends to file within five calendar days of the original due date.

The filing also stated that XWELL does not anticipate a significant change in results of operations versus the prior-year period. Investors nonetheless treated the delay as a red flag. A late filing removes a scheduled disclosure event from a company whose stockholders' equity was deeply negative at the end of fiscal 2025, whose operating cash flow has been consistently negative, and whose common stock has already lost roughly 44% of its value over the past 12 months. The revenue base has also been shrinking, with the trailing twelve-month top line near $28.3 million against $33.9 million three years earlier.

Nasdaq Bid Price Pressure Adds a Second Overhang

The selloff extends a decline that began well before this week. XWELL disclosed in October that it had received a Nasdaq notice after its closing bid price stayed below $1.00 for 30 consecutive business days between August 25 and October 6, 2026. The company was given a compliance window to regain a $1.00 bid. Tuesday's move to about $0.42 pushes the share price further from that threshold and keeps alive the possibility of a remedy such as a reverse stock split, which typically weighs on sentiment in the interim.

Thin Liquidity Amplifies the Move

XWELL is a genuinely illiquid micro-cap. Average daily volume over the past three months is roughly 44,000 shares, and the float is only about 5.8 million shares. Roughly 47,000 shares changed hands in the first 26 minutes of Tuesday's session, already more than a typical full day. With a small order book, a modest wave of sell orders can move the quote far more than the news alone would justify, which is consistent with the unusually wide intraday range of $0.302 to $0.489.

Market Context and Trading Activity

Tuesday's move was idiosyncratic. Major equity benchmarks were fractionally lower, with the S&P 500, Nasdaq-100 and Russell 2000 proxies all within 0.2% of Monday's close, so there was no broad risk-off wave to explain a double-digit decline. XWELL trades far below its 50-day moving average near $0.78 and its 200-day moving average near $1.02, and the stock has now broken below the $0.48–$0.53 shelf that held through mid-November. The intraday low of $0.302 came within reach of the 52-week low of $0.2551.

News Significance Score

The scale runs from 0, meaning no meaningful news and a normal move for the stock, to 100, meaning transformative news and an extreme, rare move. XWELL scores 52 out of 100. The verified news is moderate in weight: a short delay in a routine quarterly report, with no preliminary results disclosed, is material for a company of this size because it removes a scheduled catalyst and revives confidence concerns, but it is not a transformation of the investment case. The price move was unusual: at 15.32%, it was about 4.5 times the stock's average daily swing of roughly 3.4% over the past 60 sessions and the largest single-session decline in that stretch. Moderate news combined with a rare, high-volume move produces a mid-range score.

What Comes Next for XWELL

  • The delayed filing itself. The Form 10-Q is expected within five calendar days of the original due date. Its arrival, and any change in tone or disclosure, is the nearest scheduled information event.
  • Third-quarter expectations. Consensus ahead of the report points to a loss of about $1.00 per share on roughly $2.4 million of revenue, reflecting the wind-down of testing revenue.
  • The XpresSpa and XpresTest sale. Shareholders approved the divestiture to Express Wellness Group at an October 28 special meeting. Approval is not closing; completion and the use of proceeds remain open questions.
  • Bid price compliance. How the company addresses the Nasdaq deficiency, and on what timetable, will shape sentiment into year-end.
  • Risks. Negative equity, ongoing cash use and shareholder dilution are unresolved, and a thin order book means outsized moves in either direction remain likely.

Trending AI Robots

Tickeron's Trending AI Robots page curates the strongest currently performing automated strategies from a library of hundreds of AI trading bots spanning thousands of tickers. Because bots differ by strategy logic, holding timeframe, performance metrics and the symbols they trade, the trending list offers a useful cross-section of what is working in present market conditions rather than a single fixed approach. Review the current leaders to see which strategies are keeping pace with today's volatility.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XWEL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


XWEL's RSI Indicator slumps into oversold zone

The RSI Oscillator for XWEL moved into overbought territory on November 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

XWEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XWEL as a result. In 81 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for XWEL turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 41 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XWEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XWEL entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.728) is normal, around the industry mean (67.298). P/E Ratio (-0.113) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.220) is also within normal values, averaging (9.775).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. XWEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XWEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -8%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 23%. ADVB experienced the highest price growth at 8%, while XGN experienced the biggest fall at -47%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -19%. For the same stocks of the Industry, the average monthly volume growth was -30% and the average quarterly volume growth was -53%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 45
SMR Rating: 78
Profit Risk Rating: 87
Seasonality Score: 22 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a spa service

Industry MedicalSpecialties

Industry
Other Consumer Services
Address
254 West 31st Street
Phone
+1 212 750-9595
Employees
280
Web
https://www.xwell.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.